Outset Medical annual stock-based compensation
2018
2019
2020
2021
2022
2023
2024
2025
Outset Medical Stock-Based Compensation Growth & History (OM)
Outset Medical's stock-based compensation was $15.6M for fiscal 2025.
View full Outset Medical company overviewOutset Medical annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $15.6M | −$13.7M | −46.80% |
| 2024 | 2024-12-31 | $29.4M | −$9.3M | −24.02% |
| 2023 | 2023-12-31 | $38.6M | $11.4M | +42.02% |
| 2022 | 2022-12-31 | $27.2M | $9.8M | +55.94% |
| 2021 | 2021-12-31 | $17.4M | −$4.0M | −18.63% |
| 2020 | 2020-12-31 | $21.4M | $20.6M | +2327.97% |
| 2019 | 2019-12-31 | $883,000 | $95,000 | +12.06% |
| 2018 | 2018-12-31 | $788,000 | — | — |
Outset Medical quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.7M | −$800,000 | −22.88% |
| Q1 2026 | 2026-03-31 | $3.5M | $476,000 | +15.99% |
| Q4 2025 | 2025-12-31 | $4.1M | −$882,000 | −17.84% |
| Q3 2025 | 2025-09-30 | $5.1M | −$1.3M | −20.48% |
| Q2 2025 | 2025-06-30 | $3.5M | −$6.3M | −64.40% |
| Q1 2025 | 2025-03-31 | $3.0M | −$5.2M | −63.71% |
| Q4 2024 | 2024-12-31 | $4.9M | −$4.2M | −45.65% |
| Q3 2024 | 2024-09-30 | $6.4M | −$4.5M | −41.36% |
| Q2 2024 | 2024-06-30 | $9.8M | −$285,000 | −2.82% |
| Q1 2024 | 2024-03-31 | $8.2M | −$335,000 | −3.92% |
| Q4 2023 | 2023-12-31 | $9.1M | $1.7M | +23.73% |
| Q3 2023 | 2023-09-30 | $10.9M | $3.5M | +46.61% |
| Q2 2023 | 2023-06-30 | $10.1M | $2.7M | +36.30% |
| Q1 2023 | 2023-03-31 | $8.5M | $3.5M | +70.56% |
| Q4 2022 | 2022-12-31 | $7.4M | $2.6M | +53.44% |
| Q3 2022 | 2022-09-30 | $7.4M | $4.6M | +159.43% |
| Q2 2022 | 2022-06-30 | $7.4M | $3.5M | +88.32% |
| Q1 2022 | 2022-03-31 | $5.0M | −$846,000 | −14.46% |
| Q4 2021 | 2021-12-31 | $4.8M | −$1.5M | −23.55% |
| Q3 2021 | 2021-09-30 | $2.9M | −$11.0M | −79.41% |
| Q2 2021 | 2021-06-30 | $3.9M | $3.3M | +476.43% |
| Q1 2021 | 2021-03-31 | $5.9M | $5.3M | +908.97% |
| Q4 2020 | 2020-12-31 | $6.3M | — | — |
| Q3 2020 | 2020-09-30 | $13.9M | $13.7M | +5793.22% |
| Q2 2020 | 2020-06-30 | $683,000 | — | — |
| Q1 2020 | 2020-03-31 | $580,000 | — | — |
| Q3 2019 | 2019-09-30 | $236,000 | — | — |
Outset Medical stock-based compensation trends
Over the last five fiscal years, Outset Medical's stock-based compensation decreased from $21.4M to $15.6M, a change of −$5.8M. The latest reported quarter, Q2 2026, shows $2.7M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Outset Medical source filings ↗